Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Bel-Sar Shows Tolerability and Preliminary Antitumor Activity in NMIBC

April 7th 2025

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance

April 7th 2025

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

EC Expands SC Daratumumab’s Indication for Use in All Transplant Eligibility Settings in Newly Diagnosed Myeloma

April 7th 2025

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

Subcutaneous Amivantamab Wins EU Approval in Multiple EGFR+ Advanced NSCLC Indications

April 7th 2025

The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.

AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs

April 4th 2025

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC

April 4th 2025

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy

April 4th 2025

The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

April 4th 2025

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL

April 3rd 2025

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Dr Shore on the Importance of Addressing Gaps in Prostate Cancer Management

April 3rd 2025

Neal Shore, MD, FACS, discusses gaps in prostate cancer management and future research directions that may optimize care for high-risk localized disease.

Ongoing Research to Watch in Ovarian Cancer in 2025

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.

Kidney Cancer Awareness Month Spotlights Early Symptom Recognition, Current Challenges, and Key Treatment Advancements

April 3rd 2025

I. Alex Bowman, MD, underscores how Kidney Cancer Awareness Month enables earlier disease detection, promotes patient education, and drives vital research.

Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.

Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.

PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Avutometinib/Defactinib Combo Shows Potential in Recurrent Mesonephric Gynecologic Cancer

April 3rd 2025

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.